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During the last six years we have attempted to determine the molecular basis of 
osteogenesis irnperfecta (01) by analyzing the collagenous proteins synthesized by 
dermal fibroblasts cultured from affected individuals, their parents, and other family 
members. During that time we have studied members of more than 400 unrelated 
families, or, we estimate, between one and five percent of all families with 01 in the 
United States. These studies have, along with those from other laboratories (see REFS. 
1, 2 for reviews), provided molecular confirmation of the broad outline of clinical 
classification currently in use,' demonstrated the spectrum of mutations in collagen 
genes that give rise to clinically distinct forms of 01, helped to understand how 
mutations result in alterations in collagen metabolism, demonstrated that the study 
of proteins is an essential first step in the analysis of collagen mutations, and revealed 
a number of surprises about the nature of inheritance of different forms of 01. In this 
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paper we have detailed our own studies of the molecular basis of clinical heterogeneity 
in 01, related them to those of others, and tried to present an integrative approach 
to the relationship between mutation and phenotype. 
An EJicient Method to Screen for  Mutations in Type I Collagen That 
ptoduce Osteogenesis Imperfecta 
The vast majority of cell strains from individuals with osteogenesis imperfecta 
synthesize either decreased amounts of type I procollagen or molecules that contain 
chains of altered electrophoretic mobilities. Ordinarily we plate cells at high density 
(250,000 cells per 35 mm culture dish), allow them to attach and spread overnight, 
preincubate for four hours with ascorbate added to medium and then label for about 
16 hours with ['Hlproline (20 to 100 pC per dish using 0.7 ml of medium lacking 
serum). We harvest the medium and cell-layer proteins separately in the presence of 
protease inhibitors and analyze the pro-a chains under reducing conditions. In ad- 
dition, we analyze a separate aliquot, following limited proteolysis with pepsin to 
remove the amino-terminal propeptide extensions, under nonreducing conditions. To- 
gether, these allow us to measure the relative amounts of types I and I11 collagens 
synthesized (as well as of other collagens), the electrophoretic mobility of the con- 
stituent chains, the efficiency of secretion of the molecules, and the efficiency of 
conversion of procollagen to collagen and to the intermediates in conversion, and to 
identify the presence of interchain disulfide bonds joining two al(1) chains (direct 
analysis for the presence of cysteine substitutions in the triple-helical domain). This 
screening system has proved remarkably sensitive to mutations that change the size 
of the chains and to those which affect mobility because of changes in posttranslational 
modification. It does not identify mutations that do not affect the rate of synthesis or 
the electrophoretic mobility of chains. 
Perinatal Lethal Osteogenesis Imperfecta (OI Qpe II)  
The First Solution: A Deletion in the COLlAl Gene 
We began our investigations into the molecular basis of 01 with cells from an 
infant, previously studied by Pentinnen et,al..' that had a lethal form of 01. They 
had found that these cells secreted far less type I procollagen than normal cells but 
did secrete near normal amounts of type I11 procollagen.' In analyzing the reason for 
the defective secretion we found that the cells synthesized two species of the pro- 
al(1) chain, one that was normal and another that was shorter than normal.' The 
shortened chain was incorporated into molecules efficiently but was secreted from the 
cells at a very slow rate. Subsequent studies by Williams and Prockop confirmed these 
findings and located the deletion within the triple-helical domain! Analysis of mRNA 
by S , nuclease digestion and of genomic DNA by restriction endonuclease digestion 
indicated that the protein structure was determined by a multiexon deletion.' The 
rearrangement in the genomic structure was found, unexpectedly, to be an intron-to- 
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intron multiexon deletion that preserved the Gly-X-Y triplet structure while deleting 
triple-helical residues 327-401 from half the pro-al(1) chains."" Although these initial 
successes were provocative and genetically interesting, it was almost immediately clear 
that rearrangements did not produce the 01 type I1 phenotype in most instances.' 
Deletions Are Rare, Amino Acid Substitutions Are Common 
Analysis of the type I procollagen molecules synthesized by cell strains from more 
than 100 infants with 01 type I1 has indicated that the phenotype generally results 
from apparently subtle mutations that alter the electrophoretic mobility of the mol- 
ecules without altering their native These mutations usually occur in only 
one of the alleles encoding the chains of type I collagen and, when they have been 
analyzed, are absent from parental collagens." The vast majority of cell strains from 
infants with 01 type I1 synthesize some normal type I procollagen and some molecules 
the constituent chains of which migrate more slowly than normal. The delay in mobility 
results from increased posttranslational modification (lysyl hydroxylation and hy- 
droxylysyl glycosylation) of all chains in the affected molecules along all or a part of 
the triple-helical domain. The increased modification is accompanied by decrease in 
thermal stability of the triple helix and by decreased efficiency of secretion of the 
abnormal molecules." 
The nature of the subtle mutations that give rise to the dramatic 01 type I1 
phenotype was first illustrated by a cell strain identified by Steinmann et 01.'' in which 
cysteine was found in the pepsin resistant domain of al(I)CB6 (residues 817-1014 
of the triple helix and several residues of the carboxyl-terminal telopeptide). The cell 
strain synthesized molecules that contained one or two mutant a l (  I)  chains and both 
populations were overmodified. Cohn et a1.I' isolated portions of both COLlAl alleles 
and determined that the cysteine resulted from a single nucleotide substitution in the 
d o n  for glycine at position 988 of the triple helix. On the basis of these findings 
they suggested that most 01 type I1 cell strains harbored mutations in COLlAl that 
resulted in disruption of the Gly-X-Y triple-helical sequence, either by substitutions 
for glycine (most likely) or by small deletions or insertions that did not change the 
reading frame but either inserted or deleted amino acids. This prediction has now 
been confirmed by Bateman et a1.I' who identified substitution of arginine for glycine 
at triple-helix position 391, by Vogel et aI.'* (glycine 748 to cysteine), and by Con- 
stantinou et al." (glycine 904 to cysteine), with all mutations located in the COLlAl 
gene (that encodes the al(1) chain). In those cell strains modification of the chains 
in the molecules that incorporate the mutant chains is increased amino-terminal to 
the site of the mutation. 
Substitutions Affect Molecular Folding 
We have suggested that the extent of overmodification can be used to determine 
the approximate location in the chain of the mutant sequence'o and that overmodi- 
fication occurs either because the molecules fail to propagate triple helix beyond the 
site of the mutation or because the structure of the triple-helix amino-terminal to the 
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substitution is altered. The normal winding of triple-helix begins near the carboxyl- 
terminal end of the molecule and occurs in a processive fashion until it reaches the 
amino-terminal end.” Formation of triple helix requires a glycine in every third position 
and isomerization of cis-peptide bonds at prolyl residues to transpeptide bonds.” The 
structure is stabilized at 37°C by interchain hydrogen bonds involving the amide 
groups of glycyl residues and the carbonyl groups on adjacent chains; additional 
stabilization is provided by hydrogen bonding that involves the hydroxyl groups of 
hydroxyproline. The enzymes that produce posttranslational modification within the 
triple-helical domain of pro-a chains use only chains in random coil as substrates and 
the formation of the stable triple helix ordinarily removes the completed molecules 
from the substrate pool. 
There seem to be two classes of possible structural solutions to the question of 
overmodification. First, triple helix does not propagate beyond the substitution and 
the chains remain substrates for a substantial time (1 -2 hours). Second, although 
triple helix does propagate beyond the substitution the structure of the molecule formed 
does not inhibit enzymatic modification (i.e., the molecules have very “loose” triple- 
helical structures, possibly because the substitution changes “chain order” or in some 
other way perturbs the normal chain-chain interactions). Whatever the explanation, 
the excessively modified molecules are not efficiently secreted and some are degraded 
within the cell. Once these cells reach the extracellular space they probably interfere 
with the normal processes of fibril formation and of mineralization, although the 
mechanisms by which these occur is still not understood. 
The Nature and Position of the Substitution Determine the Phenotype 
Eight amino acid substitutions can result from single nucleotide changes in a 
glycine codon (arginine, serine, tryptophan, cysteine, aspartic acid, glutamic acid, 
valine and alanine). Of these, cysteine has been found in several cell strains (it is easy 
to identify because of the formation of dimers and thus the nature and location of 
the mutation is readily detected), arginine has been found in one, and an acidic charge 
change (presumably due to substitution of aspartic or glutamic acid) has been identified 
in another. Screening by isoelectric focusing of CNBr peptides of the chains of type 
I collagen has identified no additional charge substitutions in about 40 cell strains. 
Despite the lack of identification of the precise residue substituted, the extent of 
overmodification suggests that mutations within a significant portion of the triple- 
helical domain (most of which are probably in the COLlAl gene) can result in the 
01 type I1 phenotype. Substitutions for glycine residues in the triple-helical domain 
of the al(1) chain that result in the 01 type I1 phenotype map between residues 391 
(arginine) I’ and 988 (cysteine).””‘ Radiological-biochemical correlations suggest that 
when overmodification is most extensive the radiographic picture is worst;” thus, 
mutations near the carboxyl-terminus of the triple helix are phenotypically most severe. 
We think that all substitutions for glycine are not equivalent so that both the 
nature of the substitution and its position determine the phenotype. The evidence to 
support such an hypothesis is as follows. First, there is evidence that mutations amino- 
terminal to residue 391 can produce 01 type 11” but that other mutations in the same 
domain, probably substitutions for glycine, can result in the milder 01 type 111 
phenotype (see below). Second, substitutions of cysteine for glycine along the al(1) 
chain have markedly different phenotypes varying from the lethal 01 type I1 if the 
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substitutions occur at positions 988, 901, or 748 to 01 type 111 phenotype if the 
substitution occurs at position 526. Finally, there are suggestive data that substitutions 
further toward the amino-terminal end of the molecule have even less deleterious 
effects. Thus we think that both the position and the nature of the substituting residue 
determine the phenotype, in ways that are not yet clear: mutations near the carboxyl- 
terminal end are the most severe if they occur in al(1) and the “slope” of the 
phenotypic gradient toward the amino-terminal end may vary with the substituting 
residue. An alternative explanation for the phenotypic variation is that there are 
functional, chain-specific domains which are disrupted by the substitutions. 
More Rearrangements Have Been Found 
Although rearrangements in the genes of type I collagen are rarely found to result 
in the 01 type I1 phenotype, we have identified one multiexon deletion from the 
COLlA2 gene and a multiexon insertion in the COLlAl gene that each produce the 
phenotype. These findings suggest that, all told, rearrangements may account for fewer 
than 5% of all instances of 01 type 11. 
Cells from the first of these infants synthesized two varieties of the pro-a2(1) 
chain, one that was normal and a second that was 180 amino acids shorter than 
normal by virtue of an intron-to-intron deletion that removed the exons encoding 
triple-helical residues 586-765.19*20 The amino acid deletion predicted by genomic 
sequence determination leaves the Gly-X-Y triplet structure intact, albeit 180 residues 
shorter than normal. Molecules that contained the shortened chain were retained 
within the cell in rough endoplasmic reticulum. Although the assembly of the triple 
helix in these molecules appeared to start normally, the modification of the triple- 
helix amino-terminal to the junction was markedly increased. These findings support 
the concept (see above) that distortion of the normal triple helix may occur if the 
normal chain-chain interactions are disrupted, even by altering the relative positioning 
of the charge without disrupting the canonical triple-helix Gly-X-Y triplet 
structure. 
The remaining rearrangement we identified was a tandem duplication of an ap- 
proximately 600 base pair segment of a COLlAl allele that resulted in insertion of 
50-70 residues in the triple-helical domain of about half the pro-al(1) chains syn- 
thesized.” The insertion affected the stability of molecules that incorporated the 
abnormal chains but we were unable to determine whether the molecules containing 
one or two of the abnormal chains were least stable. 
Clinical Genetics of the OI Type N Phenotype: Germinal Mosaicism Offers an 
Alternative Explanation for Recurrence in Families 
When initially segregated as a distinct variety of 01, the perinatal lethal phenotype 
was thought to represent an autosomal recessive disorder,) an idea that was supported 
by presentation of additional families in which there had been recurrence or in which 
the proband was born to consanguineous parents.” The biochemical data presented 
by our group and by others and the more recent clinical genetic were, 
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however, most consistent with infants with the 01 type I1 phenotype resulting from 
new dominant mutations. For example, Thompson and her colleagueszJ identified no 
recurrences in 30 families. In our own study we determined an empiric recurrence 
risk of 6.7%.” Biochemical studies of the collagens synthesized by cells grown from 
several of the infants in the recurrent families indicated that they were indistinguishable 
from those of the sporadic varieties in which the mutation that was the basis of the 
phenotype had been determined. These studies were most compatible with one parent 
in each of these families being mosaic in the germ line for a population of cells that 
carried the mutation. The structure of some of the families (that is, men or women 
who had more than one affected infant with different partners) is compatible with 
this concept. We think that germinal mosaicism is the best explanation for recurrence 
of the 01 type I1 phenotype although we cannot exclude the possibility of autosomal 
recessive disease in rare families. 
Mild to Moderate Dominantly Inherited Forms of Osteogenesis Imperfecta 
(OI Type I and OI Type I V )  
Biochemical Heterogeneity 
In the course of examining collagens synthesized by cells from patients with mild 
dominantly inherited forms of 01 two patterns emerged: those from patients with 01 
type I synthesized about half the amount of normal type I procollagen while those 
from 01 type IV patients synthesized some normal type I procollagen and some 
molecules that, like those synthesized by cells from infants with 01 type 11, were 
overmodified along a portion of the triple helix. 
OI Type I Results from Mutations That Affect the “Expression ” of Type I Collagen 
Genes 
Cells cultured from most individuals with 01 type I synthesize normal amounts 
of type I11 procollagen but secrete about half the normal amount of type I procollagen.26 
In three cell strains previously studied the decrease in secretion of type I procollagen 
resulted from decreased synthesis of pro-al(1) chains. Because the chains of type I 
procollagen can be assembled as trimers that contain either two pro-al( I) chains and 
a single pro-a2( I)  chain or three pro-al( I)  chains, synthesis of half the normal amount 
of pro-al( I)  allows secretion of only half normal amounts of type I procollagen. The 
remaining pro-a2(1) is degraded. Analysis of six cell strains from individuals with 
0 1  type I indicates that both COLlAl alleles are intact suggesting that deletion of 
the entire gene is an uncommon event?’ Because mRNA levels are also decreased in 
some of these cell strains it is likely that promoter and splicing mutations will com- 
monly be found to result in 01 type 1,28*29 as might be expected with the highly complex 
structure of the genes that encode the chains of type I collagen.M 
The biochemical data are consistent with the “functional deletion” of a COLlAl 
allele and thus in large part support the linkage studies which suggest that the 01 
BYERS ef a[.: CLINICAL HETEROGENEITY OF 01 123 
type I phenotype usually results from mutations in the COLlAl  gene. None of the 
linkage studies-” has identified loss of those portions of the gene used to determine 
linkage, again supporting the concept that more subtle mutations can result in marked 
loss of function of an allele. 
01 Type I V Is Heterogenous 
Most cell strains that we have examined from individuals with 01 type IV produce 
two populations of type I procollagen molecules, those that are normal and those that 
are overmodified along a portion of the triple-helical domain. In contrast to cells from 
infants with 01 type 11, the abnormal procollagens are generally secreted quite effi- 
ciently even though the extent of modification may be similar.” 
Wenstrup and c o l l e a g ~ e s ~ ~  identified the first of these infants, a child with mild 
short stature, bowed femurs and rare fractures, born to normal parents. The cells 
from the parents synthesized only normal type I procollagen molecules while those 
from the child synthesized normal molecules and those that were overmodified along 
the full length of the chain. The thermal stability of the overmodified molecules was 
decreased similar to molecules synthesized by cells from infants with 01 type 11. These 
findings indicated that the phenotype in the child resulted from a new mutation in 
one of the genes of type I collagen but the identity of the chain in which the mutation 
occurred could not be determined. Given the difference in behavior of the molecules 
and the difference in clinical phenotype, we thought it probably resulted from a 
mutation in a COLlA2 allele. 
To further our understanding of this phenotype we undertook several additional 
investigations: first, the analysis of defects in families with 01 type IV in which linkage 
assigned the defect to the COLlA2 gene; second, analysis of individuals whose cells 
synthesized overmodified type I collagen molecules; and, finally, a deliberate search 
for point mutations that result in the appearance of cysteine within the triple-helical 
domain of a2(I). 
01 Type IV Linked to COLlA2, a Surprising Biochemical Finding 
We began our search with cells from patients in a dominant family in which linkage 
to COLlA2 had been demonstrated with high likelihood.)-’ Cells from the unaffected 
family members synthesized only normal collagens while those from the affected 
individuals synthesized and secreted normal type I and retained an overmodified species 
of type I procollagen that they appeared not to secrete at all. Two-dimensional peptide 
mapping of the retained type I procollagen indicated that some of the a2( I )  chains 
were shorter than normal by virtue of deletion of 10-20 residues located between 
residues 358 and 776.” The deletion resulted in overmodification of the pro-al(1) 
chains contained in the same molecules amino-terminal to the domain of the deletion. 
This cell strain presented uncertainties, the most pressing of which was how secretion 
of only normal molecules could result in this phenotype. Such questions remain 
unresolved and the nature of the mutation has not yet been determined. 
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Amino Acid Substitutions in &(I) Result in the OI Type IV Phenorype 
One of the cell strains most helpful to the understanding of the molecular basis 
of the 01 type IV phenotype originated from an individual in a small family in which 
the phenotype was inherited in an autosomal dominant fa~hion.)~ Cells from the affected 
individuals synthesized and secreted normal type I procollagen molecules and others 
which were overmodified along the entire length of the chains. Despite the increased 
modification the thermal stability of the abnormal molecules was normal (thus dis- 
tinguishing the effect of overmodification from stability). Separation of CNBr frag- 
ments of fibroblast collagenase-digested type I collagen, first by isoelectric focussing 
and then by size, demonstrated a basic charge change in the B-fragment of some of 
the a2(1) chains. Portions of both COLlA2 alleles were isolated using a cosmid 
vectorz0 and the nucleotide sequence of the exons encoding the domain carrying the 
charge change was determined. The mutant allele (determined by linkage analysis in 
the family) contained a single nucleotide change that resulted in substitution of arginine 
for the last glycine of the triple-helical domain (position 1012). The glycine at position 
1012 is the first "triple-helical" glycine encountered in the propagation of structure 
from the carboxyl-terminal end of the molecule. Interestingly, the effect on modification 
is striking although the thermal stability of the molecules is normal. This argues that 
extensive overmodification or the structural defect itself, first, must alter the assimi- 
lation of molecules into a matrix and, second, may interfere with normal matrix 
mineralization. The molecular findings in this family confirmed the hypothesis that 
mutations in the COLlAl and COLlA2 genes result in different phenotypes, pre- 
sumably a reflection of the functional differences between the chains. Finally, these 
findings suggested that point mutations that result in substitutions for glycine in the 
a2(I) chain are likely to be common features of the 01 type IV phenotype. 
Cysteine in the Triple-Helical Domain of &(I) Confirms That Point Mutations in 
COLIA2 Are Common Features of the OI Type IV Phenotype 
Because of the size of the CNBr peptides of the a2(I) chain and the difficulty in 
cleaving the methionyl residue that separates the large peptides a2( I)CB3 and 
a2(I)CB5 it is difficult to identify charge mutations in the chain. To assess how 
frequently point mutations (rather than small deletions or insertions) are likely to 
account for the 0 1  type IV phenotype, we analyzed cell strains from 60 different 
patients with the condition for the presence of cysteine in the triple helix:'6 Cells were 
labeled with [ "Slcysteine and the proteins secreted into the medium were digested 
with pepsin to remove the cysteine-containing propeptide extensions, and the a chain- 
size fragments were analyzed by gel electrophoresis. We found four cell strains in 
which a2(I) labeled with cysteine. In one the residue was located in a2(I)CB4, it 
was absent from type I collagen chains synthesized by both parental cell strains, the 
amino-terminal portion of type I collagen molecules was overmodified, and the phen- 
otype was similar to 01 type 111. In the other three instances, the cysteine was located 
between residues 357 and 776, the type I collagen molecules that contained the mutant 
chain were overmodified along about half the length of the triple helix and, with one 
exception, the phenotype was mild to moderate in severity. These findings confirmed 
that the 01 type IV phenotype commonly results from point mutations that, most 
likely, result in substitutions for glycine in the triple-helical domain of a2(I). 
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Substitutions in the al(I) Chain Can Produce the 01 Type IV Phenotype 
Linkage data from Sykes et d3’ and Wallis et al.” suggest that the 01 type IV 
phenotype is genetically heterogeneous. We have identified one family with 01 type 
IV cells from affected members of which synthesize normal pro-al(1) chains and 
others with a cysteine near residue 400 of the triple-helical domain:* probably similar 
to the family described by deVries and de Wet.)9 
Progressive Deforming Osteogenesis Irnpe@cta (OI Type III) 
OI Type III Often Results from Dominant Mutations 
Despite the clinical severity, 01 type I11 has been a difficult phenotype to define 
biochemically. The difficulty has its origin in both genetic heterogeneity and the nature 
of mutations in the dominantly inherited forms of the phenotype. When originally 
described 0 1  type 111 was thought to be inherited in an autosomal recessive fashion,) 
a concept supported, in part, by the more frequent consanguinity of parents” Although 
the evidence to support recessive inheritance in some individuals with such a phenotype 
is e~ce l len t ,~’~’  from a genetic point of view it is likely that many individuals with 
the phenotype represent new dominant mutations. The recurrence risk in families with 
an affected child is small and a few affected individuals have had affected children, 
consistent with the condition resulting from dominantly inherited mutations. 
Point Mutations Can Produce the OI Type III Phenotype 
We have now identified three individuals with apparent point mutations that result 
in amino acid substitutions in the a 1( I) or a2( I)  chains of type I collagen and produce 
the 0 1  type 111 phenotype. The first is a substitution of cysteine for the glycine at 
position 526 of the triple-helical domain of a l (  I).u As indicated above, this substitution 
in the al(1) chain lies between glycine residues 391 and 988 for which substitutions 
produce the more severe 01 type I1 phenotype. We think that cysteine residues may 
be less deleterious substitutions, provided they are toward the amino-terminal half of 
the chain, because of the potential of stabilizing intramolecular, interchain disulfide 
bonds. Alternatively, it is possible that glycine 526 is in a less essential location of 
the a l (1)  chain than the other residues at which substitution is lethal. In one other 
patient we have identified a charge change in al(I)CB8 (residues 124-401 of the 
triple helix) which does not result in significant overmodification of the peptide. The 
lack of significant overmodification suggests that the substitution is near the amino- 
terminal end of the peptide. Finally, we have identified a cysteine within a2(I)CB4 
that also results in the 01 type I11 phenotype and produces overmodification of a 
portion of the molecules that incorporate the mutant chain. 
These last two mutations are all near the amino-terminal end of the molecule and 
do not have major effects on posttranslational modification or on secretion. As a result, 
they can be detected only by detailed analysis of protein structure and are not readily 
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detected by most methods of screening cell strains at the protein level. Such mutations, 
as well as the possibility that some forms of 01 type I11 could result from noncollagen 
mutations, probably explains the difficulty in identifying the molecular basis of this 
form of 01. 
A Unifying Theme 
At first glance the myriad of mutations that give rise to the different phenotypes 
of osteogenesis imperfecta defies a unitary explanation. However, as the patterns 
engendered by the bulk of the mutations are examined more closely a number of 
themes emerge. First, mutations that affect the expression of the COLlAl gene (and 
probably the COLlA2 gene) are milder in their phenotypic effects than those which 
affect the structure of the protein produced thus suggesting that the structurally 
abnormal molecules contribute to the bone matrix. Second, point mutations in the 
COLlAl gene that result in substitutions for glycine residues in the triple helix are, 
in general, much more severe than those which affect the COLlA2 gene. We think 
this may result from two considerations: the role of al(1) in a molecule may be 
different than that of a2(I), and more molecules will be abnormal if mutations affect 
an al(1) chain than if they affect an a2(I) chain. Third, there is a gradient of effect 
on molecules as mutations are moved from the carboxyl-terminal end toward the 
amino-terminal end; this gradient is reflected in clinical severity and is probably 
modified by the nature of the amino acid that substitutes for glycine. Fourth, large 
rearrangements in either of the genes of type I collagen produce the lethal phenotype 
although small deletions may vary in their phenotypic expression depending on the 
chain and the location in the chain of the mutation. Finally, most forms of 01 result 
from dominant mutations. 
On the basis of our observations and those from other laboratories it has become 
possible to predict the nature of the mutation given the clinical phenotype. Despite 
the evolution of our understanding of the nature of the mutations, we still have little 
understanding of how the mutations are translated into a phenotype or why, given 
the same mutation, the phenotype may differ radically among family members. None- 
theless, these studies have served, in large part, to confirm and expand the basic clinical 
classification of 01, to provide a more rational basis for genetic counseling, and to 
begin to understand the molecular basis of this complex and heterogeneous disorder. 
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